These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15961774)

  • 1. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.
    Wick W; Weller M
    J Clin Oncol; 2005 Jun; 23(18):4235-6; author reply 4236. PubMed ID: 15961774
    [No Abstract]   [Full Text] [Related]  

  • 2. Temozolomide for melanoma: new toxicities and new opportunities.
    Gajewski TF
    J Clin Oncol; 2004 Feb; 22(4):580-1. PubMed ID: 14726506
    [No Abstract]   [Full Text] [Related]  

  • 3. Is protracted low-dose temozolomide feasible in glioma patients?
    Wong ET
    Neurology; 2006 Aug; 67(3):543-4; author reply 543-4. PubMed ID: 16894133
    [No Abstract]   [Full Text] [Related]  

  • 4. Temozolomide (Temodar).
    Wesolowski JR; Rajdev P; Mukherji SK
    AJNR Am J Neuroradiol; 2010 Sep; 31(8):1383-4. PubMed ID: 20538821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Hodgkin's lymphoma in a patient on treatment with temozolomide.
    Otty Z; Sabesan S
    Asia Pac J Clin Oncol; 2012 Dec; 8(4):e53-4. PubMed ID: 22897453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant temozolomide: how long and how much?
    Franceschi E; Tosoni A; Brandes AA
    Expert Rev Anticancer Ther; 2008 May; 8(5):663-5. PubMed ID: 18471038
    [No Abstract]   [Full Text] [Related]  

  • 7. Is protracted low-dose temozolomide feasible in glioma patients?
    Tosoni A; Cavallo G; Ermani M; Scopece L; Franceschi E; Ghimenton C; Gardiman M; Pasetto L; Blatt V; Brandes AA
    Neurology; 2006 Feb; 66(3):427-9. PubMed ID: 16476947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.
    Kong DS; Lee JI; Kim WS; Son MJ; Lim DH; Kim ST; Park K; Kim JH; Eoh W; Nam DH
    Oncol Rep; 2006 Nov; 16(5):1117-21. PubMed ID: 17016602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumocystis jirovecii pneumonia complicating the progress of a patient with glioblastoma multiforme receiving temozolomide.
    Gorospe Sarasúa L; Ureña-Vacas A; Muñoz Del Toro JR
    Arch Bronconeumol; 2016 Oct; 52(10):534-5. PubMed ID: 27021139
    [No Abstract]   [Full Text] [Related]  

  • 10. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant glioma.
    Hartmann P; Herholz K; Salzberger B; Petereit HF
    Ann Hematol; 2004 Apr; 83(4):212-7. PubMed ID: 14648028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Temozolomide in patients with a glioblastoma multiforme: new developments].
    Bromberg JE; Postma TJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.
    Villano JL; Collins CA; Manasanch EE; Ramaprasad C; van Besien K
    Lancet Oncol; 2006 May; 7(5):436-8. PubMed ID: 16648049
    [No Abstract]   [Full Text] [Related]  

  • 14. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
    Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
    Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.
    Grieco A; Tafuri MA; Biolato M; Diletto B; Di Napoli N; Balducci N; Vecchio FM; Miele L
    Medicine (Baltimore); 2015 Mar; 94(12):e476. PubMed ID: 25816026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.
    Mason WP; Cairncross JG
    Nat Clin Pract Neurol; 2005 Dec; 1(2):88-95. PubMed ID: 16932504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.
    Neyns B; Chaskis C; Joosens E; Menten J; D'Hondt L; Branle F; Sadones J; Michotte A
    Cancer Invest; 2008; 26(3):269-77. PubMed ID: 18317968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide for adult brain stem glioblastoma: case report of a long-term survivor.
    Zhang C; Yao Y; Wang Y; Chen Z; Wu J; Mao Y; Zhou L
    Int J Neurosci; 2010 Dec; 120(12):787-91. PubMed ID: 20946086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
    Wick A; Felsberg J; Steinbach JP; Herrlinger U; Platten M; Blaschke B; Meyermann R; Reifenberger G; Weller M; Wick W
    J Clin Oncol; 2007 Aug; 25(22):3357-61. PubMed ID: 17664483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for glioblastoma: the devil is in the details.
    Lesniak MS
    J Clin Oncol; 2011 Aug; 29(22):3105; author reply 3105-6. PubMed ID: 21709193
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.